Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
CASI Pharmaceuticals, Inc. logo — Bringing life-changing therapeutics to China and the world.

CASI Pharmaceuticals, Inc.

Bringing life-changing therapeutics to China and the world.

Founded 1991 United States Rockville, United States 44 employees Post Ipo Equity Biotechnology, Pharmaceutical

General Information

Company Name CASI Pharmaceuticals, Inc.
Founded Year 1991
Location United States Rockville, United States +2
Founders / Decision Makers
Team member
Employees 44
Industries Biotechnology, Pharmaceutical
Funding Stage Post Ipo Equity
Social

Get notified when CASI Pharmaceuticals, Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals, Inc. is a U.S. NASDAQ-listed biopharmaceutical company that focuses on developing and accelerating the launch of innovative therapeutics and pharmaceutical products in China, U.S., and throughout the world. With offices in Rockville, Maryland, and a wholly owned subsidiary in Beijing, China, CASI is dedicated to delivering high-quality pharmaceutical products and innovative therapeutics to patients worldwide, while targeting the China market. The company is focused on acquiring, licensing, developing, and commercializing products that address areas of unmet medical need, aiming to become the leading platform to launch medicines in the greater China market. CASI has a strong and growing product pipeline of commercially available and clinical stage drug candidates, and intends to continue acquiring additional approved and clinical stage drug candidates through in-licenses and acquisitions, as well as exploring drug candidates in preclinical development. CASI’s product portfolio encompasses diverse offerings, including an autologous anti-CD19 T-cell therapy investigative product (CNCT19), CID-103, an anti-CD38 monoclonal antibody, China regional rights to three U.S. Food and Drug Administration (FDA)-approved drugs (EVOMELA®, ZEVALIN®, and MARQIBO®), and a portfolio of FDA-approved abbreviated new drug applications (ANDAs). The most recent investment in CASI Pharmaceuticals, Inc. was a Post-IPO Equity investment on 26 June 2024. With a strong foothold in the biotechnology and pharmaceutical industries, CASI Pharmaceuticals, Inc. is positioned to drive impactful advancements in the global healthcare landscape.

Taxonomy: biopharmaceuticals, therapeutics development, oncology treatments, hematology, drug commercialization, global drug development, clinical stage drug candidates, regulatory expertise, acquisitions, licensing, drug portfolio, FDA-approved drugs, pharmaceutical products, innovative therapies, China market expansion

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 26 Jun 2024
Post-IPO Equity •••••• - 24 Mar 2021
Post-IPO Equity •••••• - 22 Jul 2020
Post-IPO Equity •••••• - 20 Mar 2018
Post-IPO Equity •••••• - 16 Oct 2017

View All 10 Funding Rounds

CASI Pharmaceuticals, Inc. Alternatives & Competitors

CASI Pharmaceuticals, Inc. vs
Lyra Therapeutics
Lyra Therapeutics

Innovative solutions for precise, localized treatments in ear, nose, and throat care.

Post Ipo Equity
51-200 employees
Biotechnology, Health Care
Compare CASI Pharmaceuticals, Inc. vs Lyra Therapeutics
CASI Pharmaceuticals, Inc. vs
Rexahn Pharmaceuticals
Rexahn Pharmaceuticals United States

TARGETING DIFFICULT TO TREAT CANCERS

Post Ipo Equity
7 employees
Biotechnology, Medical Devices
Compare CASI Pharmaceuticals, Inc. vs Rexahn Pharmaceuticals
CASI Pharmaceuticals, Inc. vs
Cloudbreak Therapeutics
Cloudbreak Therapeutics

Leading the future of eye care with efficient drug repurposing and fast-tracked clinical advancement...

Series C
11-50 employees
Biotechnology, Health Care
Compare CASI Pharmaceuticals, Inc. vs Cloudbreak Therapeutics

FAQ About CASI Pharmaceuticals, Inc.

Bringing life-changing therapeutics to China and the world.
CASI Pharmaceuticals, Inc. was founded in 1991.
CASI Pharmaceuticals, Inc. is headquartered in Rockville, United States.
CASI Pharmaceuticals, Inc. operates in the following industries: Biotechnology, Pharmaceutical.
CASI Pharmaceuticals, Inc. has approximately 44 employees.
CASI Pharmaceuticals, Inc. has completed 10 funding rounds. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to CASI Pharmaceuticals, Inc. include Lyra Therapeutics, Rexahn Pharmaceuticals, Cloudbreak Therapeutics, Innovent Biologics, Xanodyne Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
CASI Pharmaceuticals, Inc. and Lyra Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors CASI Pharmaceuticals, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes